MedTrace Logo

Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude

NCT03540901 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2021-11-05

No results posted yet for this study

Summary

This trial will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on lung water content by ultrasound at acute altitude exposure in patients with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

Interventions

DRUG

ACETAZOLAMIDE oral capsule

Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m

DRUG

Placebo oral capsule

Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m

Sponsors & Collaborators

  • National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

    collaborator OTHER_GOV

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konrad E Bloch, MD · University Hospital, Zürich

  • Talant M Sooronbaev, MD · National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

  • Michael Furian, MSc · University Hospital, Zürich

  • Silvia Ulrich, MD · University Hospital, Zürich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2018-08-02
Completion
2018-08-02

Countries

  • Kyrgyzstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03540901 on ClinicalTrials.gov